Physician profile
Zsofia Szabo
NPI 1922484468
$4,724.68
in general payments reported to CMS, 2019-2025
43 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $92.27 · 2021: $672 · 2022: $982 · 2023: $904 · 2024: $978 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.06 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Ge Healthcare | $403.62 | 2021-2025 | |
| Pfizer INC. | $338.24 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $298.34 | 2021-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $281.61 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $210.00 | 2021-2025 | Austedo Xr |
| Catalyst Pharmaceuticals, INC. | $167.39 | 2020-2024 | |
| Amgen INC. | $131.95 | 2021-2025 | Uplizna |
| Acorda Therapeutics, INC | $124.91 | 2020-2023 | Inbrija |
| Sk Life Science, INC. | $123.16 | 2021-2025 | |
| Ucb, INC. | $117.58 | 2023-2025 | Fintepla, Zilbrysq |
| Amneal Pharmaceuticals LLC | $104.37 | 2020-2024 | Rytary, Ongentys |
| Sunovion Pharmaceuticals INC. | $100.87 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $94.74 | 2021 | |
| Acadia Pharmaceuticals INC | $91.60 | 2022-2025 | Nuplazid, Daybue |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zsofia Szabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.